Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis

医学 安慰剂 交叉研究 麻醉 内科学 恶心 置信区间 慢性咳嗽 不利影响 随机对照试验 哮喘 病理 替代医学
作者
Toby Maher,Cristina Avram,Enoch Bortey,Simon P. Hart,Nikhil Hirani,Paul Molyneux,Joanna C. Porter,Jaclyn A. Smith,Thomas Sciascia
出处
期刊:NEJM evidence [New England Journal of Medicine]
卷期号:2 (8) 被引量:4
标识
DOI:10.1056/evidoa2300083
摘要

BackgroundThere are no approved therapies for cough in patients with idiopathic pulmonary fibrosis (IPF). In this small crossover trial we administered nalbuphine extended-release tablets (NAL ER) as a potential cough therapy for such patients.MethodsThis randomized, double-blind, placebo-controlled, crossover trial involved two 22-day treatment periods (NAL ER→placebo and placebo→NAL ER) separated by a 2-week washout period. NAL ER was started at a dose of 27 mg once daily and was titrated up to 162 mg twice daily at day 16. The primary end point was percent change from baseline in hourly daytime objective cough frequency as measured by an electronic cough monitor. The daytime period was defined as the patient-reported time of awakening and bedtime. Secondary end points included change in objective 24-hour cough frequency, changes in cough frequency, cough severity, and breathlessness, per patient-reported outcomes.ResultsA total of 41 patients were randomly assigned and received one or more doses of study medication. There was a 75.1% reduction in daytime objective cough frequency during the NAL ER treatment period versus the placebo treatment period of 22.6%, a 52.5 percentage point placebo-adjusted decrease from baseline (P<0.001) at day 21. There was a 76.1% (95% confidence interval, 83.1 to 69.1) decrease in the 24-hour objective cough frequency with NAL ER, versus a 25.3% (43.9 to 6.7) decrease with placebo, a 50.8 percentage point placebo-adjusted change. Nausea, fatigue, constipation, and dizziness were more common with NAL ER than with placebo.ConclusionsIn this short-term crossover trial, NAL ER reduced cough in individuals with IPF. Larger and longer trials are needed to assess the impact on cough versus drug adverse effects. (Funded by Trevi Therapeutics; ClinicalTrials.gov number, NCT04030026.)

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
聪明的鹤完成签到 ,获得积分10
刚刚
HappyFlight9898完成签到,获得积分10
2秒前
livra1058完成签到,获得积分10
3秒前
GraceWu完成签到,获得积分10
4秒前
lwtsy完成签到,获得积分10
5秒前
简单幸福完成签到 ,获得积分10
5秒前
MEMSforever发布了新的文献求助10
7秒前
烤全鱼呢关注了科研通微信公众号
8秒前
lpx43完成签到,获得积分10
10秒前
吴大宝完成签到,获得积分10
13秒前
15秒前
跳跃的访琴完成签到 ,获得积分10
15秒前
wind完成签到 ,获得积分10
21秒前
烽烽烽发布了新的文献求助10
22秒前
要努力坚持啊完成签到,获得积分10
23秒前
言悦完成签到,获得积分10
23秒前
小可完成签到 ,获得积分10
26秒前
Minjalee完成签到,获得积分10
26秒前
lily完成签到,获得积分10
28秒前
GJL发布了新的文献求助10
29秒前
沧海一粟米完成签到 ,获得积分10
30秒前
luoziwuhui完成签到,获得积分10
32秒前
Gavin完成签到,获得积分10
37秒前
风衣拖地完成签到 ,获得积分10
39秒前
June完成签到 ,获得积分10
40秒前
匆匆赶路人完成签到 ,获得积分10
44秒前
认真的白莲完成签到,获得积分10
46秒前
Yuuuu完成签到 ,获得积分10
47秒前
万元帅完成签到 ,获得积分10
48秒前
科研小南瓜完成签到 ,获得积分10
48秒前
娟儿完成签到 ,获得积分10
48秒前
啦啦啦啦完成签到 ,获得积分10
50秒前
PandaC完成签到,获得积分10
52秒前
GJL完成签到,获得积分20
53秒前
54秒前
共享精神应助谦虚采纳,获得10
57秒前
风中梦蕊完成签到 ,获得积分10
59秒前
852应助YC采纳,获得10
1分钟前
llbeyond应助科研通管家采纳,获得30
1分钟前
和平使命应助科研通管家采纳,获得10
1分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052675
求助须知:如何正确求助?哪些是违规求助? 2709898
关于积分的说明 7418335
捐赠科研通 2354494
什么是DOI,文献DOI怎么找? 1246139
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921